PATENT CLAIM ANALYSIS

Application Number: 15762602
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "062000"]

Abstract:
The present invention refers to a combination of hyaluronic acid, chondroitin sulfate in combination with at least one antacid agent, in particular magaldrate, for the prevention or treatment of gastric hyperacidity and gastroesophageal reflux and related pathologies thereof. More particularly, the combination is used for the preparation of oral compositions with at least one pharmaceutical carrier and advantageously that comprise a bioadhesive agent as well.

Claim (Index 9):
The pharmaceutical composition according to  claim 6 , wherein it is liquid and in the form of unit doses, each comprising:\n a. sodium hyaluronate in an amount of 30 to 100 mg; b. sodium chondroitin sulfate in an amount of 80 to 200 mg; c. magaldrate in an amount of 400 to 600 mg; and d. at least one bioadhesive polymer in a total amount of 100 to 400 mg.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 1.39216
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14137493', '12991776', '09967977', '15105595', '13390084']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7566469516215081
- 35 USC 102 Novelty (BERT): 0.5173059818157283
- Combined Prediction Score: 0.7327128546409301
- Mean Citation Score: 245.46694
- Max Citation Score: 306.4786
- Similarity Product: 215.0939119801283

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test